Clinical Trials on Multiple+Endocrine+Neoplasia

Total 129728 results

National Cancer Institute (NCI)

Completed

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
University of California, Los Angeles

Unknown

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Relapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple Sclerosis

United States
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
University of Missouri-Columbia

Withdrawn

Distal Pancreatectomy With Partial Splenectomy for Pancreatic Tumors

Tumor of Exocrine Pancreas

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation

Recruiting

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (INsIDER)

Multiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
M.D. Anderson Cancer Center

Withdrawn

Difference in the Estimation of Prognosis

Malignant Neoplasms of Independent (Primary) Multiple Sites
University of South Florida
Boston Children's Hospital

Completed

Access to Resources for Patients With PTEN Hamartoma Tumor Syndrome

PTEN Gene Mutation

United States
Huazhong University of Science and Technology

Unknown

Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion

Lymphatic Metastasis | Pancreas Neoplasms | Neoplasm Metastases | Unknown Primary Neoplasm Metastasis

China
Instituto do Cancer do Estado de São Paulo

Recruiting

Thermal Ablation of Cervical Metastases From Thyroid Carcinoma

Medullary Thyroid Cancer | Lymph Node Metastases | Thyroid Neoplasia | Well-Differentiated Thyroid Cancer

Brazil
Mayo Clinic

Completed

Minimally Invasive Detection of Lymphatic Micrometastases in Pancreatic Cancer (Sonoma)

Pancreatic Cancer

United States
The Cleveland Clinic
University Hospitals Cleveland Medical Center

Completed

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant (CARAMEL 2)

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
NYU Langone Health
National Cancer Institute (NCI)

Terminated

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Thrombocytopenia | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

Hamartoma Syndrome, Multiple | Cowden's Disease

United States
M.D. Anderson Cancer Center

Active, not recruiting

Expectations Regarding Mobility and Self-Care

Malignant Neoplasms of Independent (Primary) Multiple Sites | Benign Neoplasms

United States
Istituto Clinico Humanitas

Active, not recruiting

An Image-guided SBRT for Adrenal Gland Metastasis in Oligometastatic Patients

Adrenal Gland Metastases

Italy
Federation Francophone de Cancerologie Digestive

Completed

Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (EVACEL)

Neuroendocrine Tumors | Hepatic Metastases | Metastases

France
M.D. Anderson Cancer Center

Withdrawn

The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms

Malignant Neoplasms of Independent (Primary) Multiple Sites

United States
City of Hope Medical Center

Completed

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Smoldering Multiple Myeloma | Refractory Multiple Myeloma

United States
Rigshospitalet, Denmark
Odense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaborators

Recruiting

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis (DanNORMS)

Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Denmark
Erasmus Medical Center

Not yet recruiting

Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study Hydrocortisone Treatment for Symmetric Lipomatosis Associated With Neuropathy (SLN): an N-of-1 Study (N-of-1 SLN)

Symmetric Lipomatoses, Multiple

Netherlands
Brigham and Women's Hospital
Massachusetts General Hospital

Recruiting

Novel Assessment of Synaptic Density in Progressive MS

Multiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
University of Minnesota
Mallinckrodt

Terminated

ACTH in Progressive Forms of MS

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple Sclerosis

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer (RAD-THYR)

Thyroid Cancer

France
Eli Lilly and Company

Completed

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Pancreatic Neoplasms | Metastases, Neoplasm

United States, France, United Kingdom, Germany, Taiwan, Spain, Belgium, Portugal, Peru, Austria, Italy, Sweden, Netherlands, Venezuela, Argentina, Australia, Colombia, Greece
Hospices Civils de Lyon

Recruiting

Pediatric Immune Response to Multi-Organ Dysfunction (PedIMOD)

Multiple Organ Dysfunction Syndrome

France
Queen Mary University of London
Takeda Pharmaceuticals International, Inc.

Recruiting

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis (SIZOMUS)

Relapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United Kingdom
University of California, San Francisco
United States Department of Defense

Recruiting

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy (ReVIVE)

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis Benign

United States
Icahn School of Medicine at Mount Sinai
Columbia University; New York Stem Cell Foundation Research Institute

Completed

Mitochondrial Dysfunction and Disease Progression

Clinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Banc de Sang i Teixits
Vall d'Hebron Research Institute (VHIR)

Completed

Autologous Mesenchymal Stromal Cells for Multiple Sclerosis (EMMES)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

Spain
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Mayo Clinic

Completed

Adrenalectomy for Solitary Adrenal Gland Metastases

Adrenal Gland Metastases | Adrenalectomy
Eli Lilly and Company

Completed

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Neoplasms | Neoplasm Metastasis | Pancreatic Cancer

United States, Germany, Spain, Belgium, Italy, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Sheba Medical Center

Completed

Ultra-Low Dose CT Denoising for Lung Nodule Detection

Pulmonary Nodule, Multiple

Israel
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Tarceva and Capecitabine for Pancreatic Cancer

Neoplasm Metastasis | Pancreatic Cancer

United States
OncoSil Medical Limited

Recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. (OSPREY)

Neoplasms | Neoplasms by Site | Endocrine System Diseases | Pancreatic Diseases | Digestive System Neoplasm | Digestive System Disease | Pancreatic Neoplasm | Endocrine Gland Neoplasm

Spain, United Kingdom
All4Cure
GlaxoSmithKline

Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, Refractory

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, Canada
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
University of Southern California
National Cancer Institute (NCI); Celgene Corporation

Terminated

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States
IRCCS San Raffaele

Recruiting

EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients (EUPhORIC)

Pancreatic Cancer | Pancreatic Adenocarcinoma

Italy

Clinical Trials on Multiple+Endocrine+Neoplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations